Many studies are still being conducted to determine the specific symptoms caused by the Delta variant.
Delta variant is causing a new wave of COVID-19 epidemics in many countries
According to a study conducted in the United Kingdom (where the Delta strain predominates), symptoms such as cough and loss of smell that were previously common have become less common in COVID-19 patients due to this variant Delta.
The most common symptoms include Fever (100 degrees F, approximately 38 degrees C or higher); headache; sore throat; snivel; dry cough; tired.
Other symptoms include Body aches; muscle or joint pain; shortness of breath; sputum secretion; conjunctivitis; stuffy nose; nausea or vomiting; diarrhea; chills; dizzy; rash or skin discoloration on fingers or toes.
Severe symptoms include Shortness of breath or difficulty breathing; persistent chest pain or heaviness in the chest; speechlessness; loss of appetite; high body temperature; pale lips or face.
Symptoms that may require hospitalization include: Serious neurological complications such as coma, encephalitis, stroke or nerve damage; shortness of breath; chest pain or tightness; Extreme disorientation, and altered mental status may include seizures.
Symptoms appear about 5-6 days after infection with SARS-CoV-2, however, this period can range from 1-14 days.
Compare with previous variations
Studies have reported that the Delta variant:
– 50% more contagious than the original COVID-19 alphavirus strain.
– Associated with a higher risk of complications and hospitalization.
– Infectious and rapidly growing.
– Affects more young people – the prevalence of this variant is higher among young people.
– Increased risk of hospitalization for unvaccinated people.
Effective against Delta variant of some vaccines
Several vaccines against COVI-19 are effective against the Delta variant.
Effective prevention of Delta variant symptomatic disease was 36% after the first dose and 88% after the second dose.
Effective in preventing hospitalization (moderate and severe) at 94% after the first dose and 96% after the second dose.
Using technology similar to that of Pfizer; therefore, the researchers believe it will provide the same protection as the Pfizer vaccine. Studies are underway to determine exactly how much protection this vaccine offers against the Delta variant.
Reports showed it to be 60% effective against symptomatic disease caused by the Delta variant and 93% effective against complications and hospitalization after both doses.
Vaccines Johnson & Johnson
Proven to be effective against variations Delta, although no high protective effect as vaccine Pfizer or Moderna.
Some researchers believe that this vaccine has similar results to the AstraZeneca vaccine, although many studies are underway that are inconclusive.